Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts

Siham Moatassim-Billah , Camille Duluc (1) , Rémi Samain (2) , Christine Jean (1) , Aurélie Perraud (3, 4) , Emilie Decaup (1) , Stéphanie Cassant-Sourdy (5) , Youssef Bakri (6) , Janick Selves (7) , Herbert Schmid (8) , Yvan Martineau (1) , Muriel Mathonnet (4, 3) , Stephane Pyronnet (1) , Corinne Bousquet (1)

1 CRCT - Centre de Recherches en Cancérologie de Toulouse
2 UGA UFRP - Université Grenoble Alpes - UFR Pharmacie
3 HCP - Homéostasie Cellulaire et Pathologies
4 Service de Chirurgie digestive, endocrinienne et générale [CHU Limoges]
5 I2MC - Institut des Maladies Métaboliques et Cardiovasculaires
6 CIML - Centre d'Immunologie de Marseille - Luminy
7 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
8 Novartis Pharmaceuticals

Domaines: Sciences du Vivant [q-bio]; Cancer

Siham Moatassim-Billah, Camille Duluc, Rémi Samain, Christine Jean, Aurélie Perraud, et al.. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts. Oncotarget, 2016, 7 (27), ⟨10.18632/oncotarget.9296⟩. ⟨hal-02421440⟩